leisure time -WSS

leisure time

author：explore 2025-09-29 17:02:25 - browse：24

Photography of the US department of health and human services in Silver Spring MD — Manuel Balce Ceneta/AP

An increasing number of medical device companies are submitting fabricated and unreliable data, the Food and Drug Administration noted Tuesday morning. The data comes from third-party labs hired by device firms to test the quality of their products.

Triple-check your data or we’ll reject your device, the FDA warned.

The goal of third-party testing is to ensure a device meets the FDA’s standards in a range of areas, including biocompatibility, sterility, and mechanical performance. The agency wrote that it has noticed an uptick in false data submissions in recent years, particularly from facilities based in China and India. In some cases, the facilities will send data copied from previous device submissions.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Naloxone nonprofit donates 200,000 doses after FDA approval

Wikipedia

WSS

SEC charges former device maker CEO with $41 million fraud

American woman, child freed after being kidnapped in Haiti last month

In Spain, a hospital brews its own CAR

Can sheer will power keep patients alive in their dying hours?

Can sheer will power keep patients alive in their dying hours?

Wegovy trial has doctors encouraged over new possibilities

explore

leisure time

focus

In Memoriam: Notable people who died in 2023

Why health records don't always know when patients are dead

Peter Hotez and the public health issue of online harassment

Why failed clinical trials don’t always spell doom for a new drug

How one medical school became remarkably diverse

SNAP should offer more nutrition education

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Carvykti CAR

Alkermes shareholders re

Bristol Myers buys into radiopharmaceuticals with RayzeBio

hotspot

Anavex keeps shifting the goalposts in its clinical trials

CRISPR gene editing developments we’re watching in 2024

CRISPR gene editing developments we’re watching in 2024

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

In Spain, a hospital brews its own CAR

explore

Wikipedia

Wikipedia

focus